Friday, March 22, 2013

Factoid Friday #111

The IMS Institute for Health Informatics report, The Global Use of Medicines: Outlook Through 2016, forecasts that global launches for new molecular entities (NMEs) will rebound to 32 to 37 per year through 2016 – up from fewer than 30 in four of the last seven years.

SecondOpinion - ALS

SecondOpinion, a medical series exploring illnesses one at a time featuring a panel of physicians and other experts assessing individual cases, tackles amyotrophic lateral sclerosis (ALS). In this heartfelt episode, experts present data and Gary Temoyan shares his story, talking about his diagnosis, treatments, progression, and symptom management, which is maximizing his quality of life for as long as possible.

Thursday, March 21, 2013

Perspective Wednesday #115

"Healing doesn't mean the damage never existed. It means the damage no longer controls our lives.”  Unknown

Blocked From Drug Trials

Even when there are promising drug trials, they tend to exclude people who have had ALS for more than two or three years — people like Catherine Wolf (pictured below) who has lived with the disease for 17 years. The biology of the disease varies depending on how quickly it progresses and most trials require that participants be able to breathe on their own.

Catherine and I agree that there may be drugs that slow progression at different stages of the disease. Many believe that ALS is not one disease, but rather a spectrum of diseases. Therefore, shouldn't clinical trials include people with more advanced ALS?

Sunday, March 17, 2013

Spiritual Sunday #103

"But those who hope in the Lord will renew their strength. They will soar on wings like eagles; they will run and not grow weary, they will walk and not be faint." Isaiah 40:31 (NIV)